Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5‐year results from the nishi‐nippon group of the adjuvant chemoendocrine therapy for breast cancer organization

Background. A randomized adjuvant trial was conducted from October 1982 to January 1985 to evaluate the addition of tamoxifen (TAM) to combination chemotherapy with perioperative mitomycin C (MMC) and ftorafur (FT) for patients with estrogen receptor (ER)‐positive tumors and the addition of PSK, a biologic response modifier, to MMC + FT chemotherapy for patients with ER‐negative tumors in operable Stage IIA, IIB, and IIIA cancer. The doses used were 20 mg of oral TAM daily, 600 mg of oral FT daily, and 3 g of oral PSK daily for 2 years. Intravenous MMC (13 mg/m2) was given on the day of operation.

[1]  C. Redmond,et al.  Evaluation of the worth of Corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer: Eight‐year results from the national surgical adjuvant breast and bowel project B‐10 , 1990, Cancer.

[2]  R. Gray,et al.  Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An eastern cooperative oncology group trial , 1990, Cancer.

[3]  J. Ingle,et al.  Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5‐fluorouracil, prednisone adjuvant therapy in premenopausal women with node‐positive breast cancer , 1989, Cancer.

[4]  G. Bonadonna,et al.  Current status of adjuvant chemotherapy for breast cancer. , 1987, Seminars in oncology.

[5]  C. Redmond,et al.  Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Brenner,et al.  The relationship of clinical status and therapeutic modality to natural killer cell activity in human breast cancer , 1985, Cancer.

[7]  L. Holsti,et al.  Levamisole in the treatment of stage II breast cancer five‐year follow‐up of a randomized double‐blind study , 1985, Cancer.

[8]  J. Crowe,et al.  Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up. , 1984, Surgery.

[9]  C. Osborne,et al.  Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. , 1984, Cancer research.

[10]  P. Schlag,et al.  Chemosensitivity testing of human neoplasms using the soft agar colony assay. , 1984, Cancer treatment reviews.

[11]  Terry L. Smith,et al.  Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial , 1984, Cancer.

[12]  F. Ansfield,et al.  Phase I-II studies of oral tegafur (ftorafur). , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Y. Nomura,et al.  Steroid hormone receptors and clinical usefulness in human breast cancer , 1980, Cancer.

[14]  C. Redmond,et al.  L‐phenylalanine mustard (L‐PAM) in the management of primary breast cancer: An update of earlier findings and a comparison with those utilizing L‐PAM plus 5‐fluorouracil (5‐FU) , 1977, Cancer.

[15]  M. Lippman,et al.  The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. , 1976, Cancer research.